Unraveling the Complexities of Cutaneous Lymphoma

Conclusions

• Cutaneous lymphomas are best understood as a heterogeneous group within non-Hodgkin lymphoma that must be separated into primary cutaneous disease and secondary skin involvement from systemic lymphoma.
• Primary cutaneous lymphomas are predominantly cutaneous T-cell lymphomas, with mycosis fungoides and Sézary syndrome being the most common and clinically important subtypes.
• Diagnosis of CTCL is often difficult and usually requires clinicopathologic correlation, multiple biopsies from different sites or times, and ancillary studies such as immunostaining and clonality testing.
• When CTCL is suspected, clinicians should evaluate all major compartments of disease including skin, blood, lymph nodes, and viscera before final staging.
• Peripheral blood flow cytometry, clonality studies, and selective imaging and biopsy help identify extracutaneous involvement, especially in Sézary syndrome.
• TNMB staging remains the most validated prognostic framework and is central to treatment selection in MF/SS despite its imperfections.
• CTCL presents with a wide spectrum of morphologies and can mimic eczema, psoriasis, and other inflammatory dermatoses, making recognition challenging.
• Clinical appearance can vary by skin tone, with erythema, hyperpigmentation, violaceous patches, and subtle erythroderma potentially leading to underrecognition in darker skin.
• Black patients in the cited multicenter cohort appeared to present with more advanced disease and worse outcomes in older age groups, suggesting meaningful racial disparities in CTCL presentation and prognosis.
• New prognostic tools are being developed because staging alone is insufficient to fully predict outcome and guide therapy.
• Overall diagnosis, prognostication, and management of CTCL are difficult but increasingly refined by better staging, pathology review, and emerging prognostic indices.